



Boule Diagnostics – Nomination Committee for the 2024 Annual General Meeting

The Annual General Meeting, ("AGM"), 2023 of Boule Diagnostics AB (publ), ("Boule"), decided that a Nomination Committee based on the ownership structure as per September 30, 2023, will be appointed to propose for the AGM of 2024 the following items:

1. chairman of the AGM,
2. members of the board of directors,
3. chairman of the board,
4. remuneration to the members of the board and remuneration for additional committee work for each board member,
5. auditor in charge,
6. remuneration to the auditor,
7. changes to the principles and instructions for the Nomination Committee, to the extent deemed necessary, and
8. other items that fall on the Nomination Committee in accordance with The Swedish Corporate Governance Code.

Boule's largest shareholders at the date above were AB Grenspecialisten, Svolder AB and Thomas Eklund, who combined represent just below 35 percent of share capital and votes. Said shareholders have in turn nominated Tomas Risbecker (Svolder AB), Erik Ivarsson (AB Grenspecialisten) and Thomas Eklund. The Nomination Committee has subsequently constituted and elected Erik Ivarsson as chairman of the committee and Torben Jörgensen, the chairman of the board, as an adjunct member.

Shareholders who wish to contact the Nomination Committee are welcome to contact the committee's chairman, Erik Ivarsson, by email at erik.ivarsson@grenspecialisten.com. To ensure that proposals will have enough time to be evaluated properly, proposals should be submitted by February 1, 2024, at the latest.

For further information, please contact:

Jesper Söderqvist, CEO and Group President, Boule Diagnostics AB, phone. +46 (0)70-689 05 90
Jan Benjaminson, CFO, Boule Diagnostics AB, phone. +46 (0)70-666 93 88

About Boule Diagnostics AB (publ)

Boule Diagnostics AB (publ) is a global diagnostics company specializing in near-patient, decentralized blood diagnostics and one of the few companies in the global diagnostics market that conducts its own development, manufacturing and marketing of instruments and consumables for blood diagnostics. The Company primarily serves hospitals, clinics, laboratories and other diagnostics companies to which it offers complete systems for blood diagnostics (hematology) in both the human and veterinary areas. Boule has strong positions in important emerging markets such as in Asia and in recent years has improved its position in the fast-growing veterinary market. Operations are conducted through operating subsidiaries in Sweden, the United States, Mexico and Russia. The Group reported net sales of SEK 548 million in 2022 and has more than 200 employees. Sales are conducted globally, predominantly through the company's 200 or so distributors in over 100 countries, supported by Boule's own local sales and service personnel. Boule has been listed on Nasdaq Stockholm since 2011. www.boule.com